Immunological mechanisms operative in allergen-specific immunotherapy

International Archives of Allergy and Immunology

Volumn 119, Issue 1, 1999, Pages 1-5

  Ebner, Christof ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Immune deviation; Immunotherapy, specific; Th1; Th2; Tolerance; Type I allergy

Indexed keywords

ALLERGEN; HYMENOPTERA VENOM; IMMUNOGLOBULIN E; PLACEBO;

ALLERGY; DESENSITIZATION; DOUBLE BLIND PROCEDURE; HUMAN; HYPERSENSITIVITY; IMMUNOTHERAPY; INHALATION; PRIORITY JOURNAL; SHORT SURVEY; TARGET ORGAN;

ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 0032910288     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000024168     Document Type: Short Survey

References (62)

1. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR: Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991; 302:265-269.
2. Ottolani C, Pastorello E, Moss RB, Hsu YP, Restuccia M, Joppolo G, Miadonna A, Cornelli U, Halpern G, Zanussi C: Grass pollen immunotherapy: A single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. J Allergy Clin Immunol 1984;73:283-290.
3. Bousquet J, Hejjaoui A, Skassa-Brociek W, Guerin B, Maasch HJ, Dhivert H, Michel FB: Double-blind, placebo-controlled immunotherapy with mixed grass pollen allergoids. I. Rush immunotherapy with allergoids and standardized grass pollen extract. J Allergy Clin Immunol 1987;80:591-598.
4. Norman PS, Winkelwerder W, Lichtenstein L: Immunotherapy of hay fever with ragweed antigen E: Comparisons with whole pollen extract and placebos. J Allergy 1968;42:93-108.
5. D'Amato G, Kordash TR, Liccardi G, Lobefalo G, Cazzola M, Freshwater LL: Immunotherapy with Alpare in patients with respiratory allergy to Parietaria pollen: A two-year double-blind, placebo-controlled study. Clin Exp Allergy 1995;25:149-158.
6. Bousquet J, Michel FB: Specific immunotherapy in asthma: Is it effective? J Allergy Clin Immunol 1994;94:1-11.
7. Warner JO, Price JF, Soothill JF, Hey EN: Controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978;ii:912-915.
8. Wahn U, Schweler C, Lind P, Lowenstein H: Prospective study on immunologic changes induced by two different Dermatophagoides pteronyssinus extracts prepared from whole mite cultures and mite bodies. J Allergy Clin Immunol 1988;82:360-370.
9. Van Bever HP, Stevens WJ: Effect of hyposensitization upon the immediate and late asthmatic reaction and upon histamine reactivity in patients allergic to house dust mit (Dermatophagoides pteronyssinus). Eur Respir J 1992; 5:318-322.
10. Pichler CE, Maquardsen A, Sparholt S, Lowenstein H, Bircher A, Bischof M, Pichler WJ: Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy 1997;52:274-283.
11. Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM: A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978;299:157-161.
12. Müller U, Helbling A, Berchtold E: Immunotherapy with honey-bee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992;89:529-535.
13. Des Roches A, Paradis L, Ménerado J-L, Bouges S, Daures JP, Bousquet J: Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997;99:450-453.
14. Jacobsen L, Dreborg S, Moller C, Valovirta E, Wahn U, Niggemann B, Koller D, Urbanek R, Halken S, Host A, Lowenstein H: Immunotherapy as a preventive allergy treatment (abstract). J Allergy Clin Immunol 1996;97:232.
15. Bousquet J, Lockey RF, Mailing HJ : WHO Position Paper. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. Allergy 1998;53(suppl):1-42.
16. Mosbech H, Dreborg S, Madsen F, Ohlsson H, Stahl-Skov P, Taudorf E, Weeke B: High dose grass pollen tablets used for hyposensitization in hay fever patients. A one-year double-blind placebo-controlled study. Allergy 1987;42: 451-455.
17. Sabbah A, Hassoun S, Le Sellin J, André C, Sicard H: A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994;49:309-313.
18. Andri L, Senna G, Andri G, Dama A, Givanni S, Betteli C, Dimitri G, Falagiani P, Mezzelani P: Local nasal immunotherapy for birch allergic rhinitis with extract in powder form. Clin Exp Allergy 1995;97:1092-1099.
19. Welsh PW, Butterfield JH, Yunginger JW, Agarwal MW, Gleich GJ: Allergen-controlled study of intranasal immunotherapy for ragweed hay fever. J Allergy Clin Immunol 1983;71:454-460.
20. Lichtenstein LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM: IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973;70:261-271.
21. Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann U, Schenk S, Klotz F, Ebner H, Kraft D, Scheiner O: Immunological changes during specific immunotherapy of grass pollen allergy: Reduced lymphoproliferative responses to allergen and shift from Th2 to Th1 in T cell clones specific for Ph1 p 1, a major grass pollen allergen. Clin Exp Allergy 1997;27: 1007-1015.
22. Djurup R, Osterballe O: IgG subclass antibody response in grass pollen-allergic individuals undergoing specific immunotherapy. Prognostic value of serum subclass antibody levels early in immunotherapy. Allergy 1984;39:433-441.
23. Lichtenstein LM, Holtzman NA, Burnett LS: A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J Immunol 1968;101:317-324.
24. Hussain R, Poindexter RW, Ottesen EA: Control of allergic reactivity in human filariasis. Predominant localization of blocking antibodies to the IgG-4 subclass. J Immunol 1992;148: 2731-2739.
25. Birkner T, Rumpold H, Jarolim E, Ebner H, Breitenbach M, Svaril F, Scheiner O, Kraft D: Evaluation of immunotherapy-induced changes in specific IgE, IgG, and IgG-subclasses in birch pollen allergic patients by means of immunoblotting. Allergy 1989;45:418-425.
26. Jarolim E, Poulsen LK, Stadler BM, Mosbech H, Oesterballe O, Kraft D, Weeke B: A long term follow-up study of hyposensitization with immunoblotling. J Allergy Clin Immunol 1990;85:996-1004.
27. Van der Zwan JC, Flintermann J, Jankowsky IG, Kerckhaert JA: Hyposensitization to wasp venom in six hours. BMJ 1983;287:1329-1331.
28. Birnbaum J, Charpin D, Vervloet D: Rapid Hymenoptera venom immunotherapy: Comparative safety of three protocols. Clin Exp Allergy 1993;23:226-230.
29. Wierenga AE, Snoek M, DeGroot C, Chrétien I, Bos JD, Jansen HM, Kapsenberg ML: Evidence for compartmentalization of functional subsets of CD4+ T lymphocytes in atopic patients. J Immunol 1990;144:4651-4656.
30. Romagnani S: Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994;12:227-257.
31. VanNeerven RJJ, Ebner C, Yssel H, Kapsenberg ML, Lamb JR: T cell responses to allergens: Epitope specificity and clinical relevance. Immunol Today 1996;17:526-532.
32. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT: Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993; 178:2123-2130.
33. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Müller UR: Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187-4194.
34. McHugh SM, Deighton J, Steward AG, Lachmann PJ, Ewan PW: Bee venom immunotherapy induces a shift in cytokine responses from a Th2 to a Th1 dominant pattern: Comparison of rush and conventional immunotherapy. Clin Exp Allergy 1995;25:828-838.
35. Akdis CA, Akdis M, Blesken T, Wymann D, Alkan SS, Müller U, Blaser K: Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996;98: 1676-1683.
36. Varney VA, Hamid QA, Sun Y, Jacobson M, Frew AJ, Kay AB, Durham SR: Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous response. J Clin Invest 1993;92:644-651.
37. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, Kay AB, Hamid QA: Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-γ. J Allergy Clin Immunol 1996;97:1356-1365.
38. Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR: Increases in IL-12 messenger RNA + cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997;99:254-260.
39. Carballido JM, Carballido-Perrig N, Terres G, Heusser CH, Blaser K: Bee venom phospholipase A2-specific T cell clones from human allergic and non-allergic individuals: Cytokine patterns change in response to the antigen concentration. Eur J Immunol 1992;22:1357-1363.
40. Secrist H, DeKruyff RH, Umetsu DT: Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J Exp Med 1995;181:1081-1089.
41. Manetti R, Gerosa F, Guidizi MG, Biagiotti MG, Parronchi P, Piccini MP, Sampognaro S, Maggi E, Romagnani S, Trinchieri G: Interleukin-12 induces stable priming for interferon-γ (IFN-γ) production during differentiation of human T helper cells and transient IFN-γ production in established Th2 cell clones. J Exp Med 1994;179:1273-1280.
42. Constant S, Pfeiffer C, Woodard A, Pasqualini T, Bottomly K: Extent of T cell receptor ligation can determine the functional differentiation of naive CD4+ cells. J Exp Med 1995;182: 1591-1596.
43. Hsieh KH: Changes of lymphoproliferative responses of T cell subsets to allergen and mitogen after hyposensitization in asthmatic children. J Allergy Clin Immunol 1984;74:34-40.
44. Akdis CA, Blesken T, Akdis M, Wüthrich B, Blaser K: Role of interleukin in specific immunotherapy. J Clin Invest 1998;102:98-106.
45. Bellinghausen I, Metz G, Enk A, Christmann S, Knop J, Saloga J: Insect venom immunotherapy induces interleukin-10 production and a Th1-to-Th2 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997;27:1131-1139.
46. De Waal Malefyt R, Abrams J, Bennett B, Fidgor CG, DeVries JE: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-1220.
47. Del Prete GM, De Carli M, Almerigogna F, Guidizi MG, Biagiotti R, Romagnani S: Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993;150: 353-360.
48. Ebner C, Schenk S, Najafian N, Siemann U, Fischer G, Hoffmann K, Szépfalusi Z, Scheiner O, Kraft D: T cell clones (TCC) from non-allergic individuals recognize the same epitopes of Bet v 1, the major birch pollen allergen, as TCC from atopic patients. J Immunol 1995;154:1932-1940.
49. Punnonen JR, De Waal Malefyt R, Van Vlasselaer P, Gauchat JF, DeVries JE: IL-10 and viral IL-10 prevent IL-4-induced IgE synthesis by inhibiting the accessory cell function of monocytes. J Immunol 1993;151:1280-1289.
50. Enk AH, Saloga J, Becker D, Mohamadzadeh M, Knop J: Induction of hapten-specific tolerance by interleukin-10 in vivo. J Exp Med 1994;179:1397-1402.
51. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, DeVries JE, Roncarolo MG: A CD4+ T cell-subset inhibits antigen-specific T cell responses and prevents colitis. Nature 1997;389:737-742.
52. Brunner T, Heusser CH, Dahinden CA: Human peripheral blood basophils primed with interleukin-3 (IL-3) produce IL-4 in response to immunoglobulin E receptor stimulation. J Exp Med 1993;177:605-611.
53. Furin MJ, Norman PS, Creticos PS, Proud D, Kagey-Sobolka A, Lichtenstein LM, Naclerio RM: Immunotherapy decreases antigen-induced eosinophil migration into the nasal cavity. J Allergy Clin Immunol 1991;88:27-32.
54. Rak S, Roehagen O, Venge P: The effect of immunotherapy and bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol 1988; 82:470-480.
55. Creticos PS, Atkinson NF Jr, Kagey-Sobotka A, Proud D, Meier HL, Naclerio RM, Lichtenstein LM: Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy. J Clin Invest 1985;76:2247-2253.
56. Otsuka H, Mezawa A, Oshini M, Okubo K, Seki H, Okuda M: Changes in metachromatic cells during allergen immunotherapy. Clin Exp Allergy 1991;21:115-119.
57. Steiberger P, Bohle B, Padova DF, Wrann M, Liehl E, Scheiner O, Kraft D, Valenta R: Allergen-specific IgE production of committed B cells from allergic patients in vitro. J Allergy Clin Immunol 1995;96:209-218.
58. Ferreira F, Hirthenlehner K, Jilek A, Godnic-Cvar J, Breiteneder H, Grimm R, Hoffmann-Sommergruber K, Scheiner O, Kraft D, Breitenbach M, Rheinberger HJ, Ebner C: Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: Potential use of hypoallergenic isoforms for immunotherapy. J Exp Med 1996;183:599-609.
59. Ferreira F, Ebner C, Kramer B, Casari G, Briza P. Kungl AJ, Grimm R, Jahn-Schmid B, Breiteneder H, Kraft D, Breitenbach M, Rheinberger HJ, Scheiner O: Modulation of IgE reactivity of allergens by site-directed mutagenesis: Potential use of hypoallergenic variants for immunotherapy. FASEB J 1998;12: 231-242.
60. Nicodemus C, Philpi G, Jones N, Hirani S, Norman P: Integrated clinical experience with tolerogenic peptides. Int Arch Allergy Immunol 1997;113:326-328.
61. Jahn-Schmid B, Siemann U, Zenker A, Bohle B, Messner P, Unger FM, Sleytr UB, Scheiner O, Kraft D, Ebner C: Bet v 1, the major birch pollen allergen, conjugated to crystalline bacterial cell surface proteins, expands allergen-specific T cells of the Th1/Th0 phenotype in vitro by induction of IL-12. Int Immunol 1997; 9:1867-1873.
62. Goodman JS, Van Uden JH, Kobayasi H, Broide D, Raz E: DNA immunotherpeutics: New potential treatment modalities for allergic disease. Int Arch Allergy immunol 1998; 116:177-186.